1William JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. JAm-SocNephrol,2002,13(2) :470 - 479.
2Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Petit Dial Int JT Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, 1992,12( 1 ) : 14 - 27.
3Wolf G,Neilson EG. Angiotensin Ⅱ as a renal growth factor. J Am Soc Nephrol, 1993,3(9) : 1531 - 1540.
4de Gasparo M,Catt KJ, Inagami T,et al. International union of pharmacology. ⅩⅩⅢ. The angiotensin Ⅱ receptors. Pharmacol Rev,2000,52(3) :415 - 472
5Deferrari G, Ravera M, Deferrari L, et al. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin Ⅱ receptor blockers. J Am Soc Nephrol, 2002, 13 (Suppl 3) : S224 -S229.
6Thomas DW,Hoffrnan MD. Identification of macrophage receptors for angiotensin: a potential role in antigen uptake for T lymphocyte responses. J Immunol, 1984,132(6) :2807 - 2812.
7Delbaere A, Bergmarm P J, Gerry - Decoster C, et al. Periovulatory elevation of angiotensin Ⅱ in the peritoneal fluid during the human menstrual cycle. J Clin Endocrinol Metab, 1996,81 (8) :2810- 2815.
8Kiribayashi K, Masaki T, Naito T, et al. Angiotensin Ⅱ induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int, 2005, 67(3): 1126 -1135.
9Noh H,Ha H,Yu MR,et al. Angiotensin Ⅱ mediates high glucose- induced TGF- betal and fibronectin upregulation in HPMC through reactive oxygen species. Petit Dial Int, 2005,25 (1):38-47.
10Peters H,Border WA, Noble NA. Targeting TGF- beta over- expression in renal disease: maximizing the antifibrotic action of angiotensin Ⅱ blockade. Kidney Int, 1998,54(5) : 1570 - 1580.
